UK's Largest Pharmacy Distributor Introduces RESPeRATE Hypertension
Treatment Device Into Country's Retail Market
NEW YORK and LONDON, Sept. 17 /PRNewswire/ -- InterCure, Ltd. (TASE: INCR), today announced that its RESPeRATE(R) hypertension treatment device, clinically-proven in 10 peer-reviewed studies to significantly lower blood pressure, will launch into retail distribution in the United Kingdom through Mashco, Ltd., the country's largest distributor of healthcare diagnostics to the independent pharmacy market. The partnership marks a milestone for RESPeRATE, which has previously been sold directly to consumers through its website, http://www.resperate.com and through online resellers such as Amazon.com.
According to the terms of the agreement, Mashco will initially introduce RESPeRATE into 100 of its key retail partner locations beginning this month, with an emphasis on prominent stores which offer diagnostic blood pressure testing. Mashco will provide pharmacist education, patient information and an assortment of merchandising programs to introduce RESPeRATE as a valuable addition to patients' hypertension management regimens. In-store marketing will highlight the importance of combining diagnostic and therapeutic solutions to best manage hypertension under the guidance of a physician and pharmacist. Full rollout of RESPeRATE into the independent pharmacy market in the UK will occur immediately following the 100-store launch. Mashco currently serves 3,000 pharmacies in the United Kingdom.
"RESPeRATE's tremendous growth has been fueled by the massive numbers
of frustrated hypertension sufferers who seek our safe, efficacious,
non-drug treatment option," said Erez Gavish, president and CEO of
InterCure. "Yet, two-thirds of our prospective customers tell us that they
would prefer to buy RESPeRATE through their local pharmacy. InterCure's
move into the UK independent ph
|SOURCE InterCure, Ltd.|
Copyright©2007 PR Newswire.
All rights reserved